Skip to main content

Evaluation of decision-making capacity in patients with dementia: challenges and recommendations from a secondary analysis of qualitative interviews

Abstract

Background

Evaluation of decision-making capacity to consent to medical treatment has proved to be difficult in patients with dementia. Studies showed that physicians are often insufficiently trained in the evaluation of decision-making capacity. In this study, we present findings from a secondary analysis of a qualitative interviews with physicians. These interviews were initially used to assess usability of an instrument for the evaluation of decision-making capacity. By looking at difficult cases of decision-making capacity evaluation in patients with dementia, we provide recommendations for such evaluations in clinical practice.

Methods

We used thematic coding to analyse physicians’ narratives of problematic decision-making capacity evaluations in patients with dementia to uncover challenging issues of decision-making capacity evaluation.

Results

In this study, decision-making capacity evaluations in patients with dementia were mainly perceived as challenging when they pertained to treatment refusals and treatment unrelated circumstances, such as psychiatric consultation, advance directives, and new living arrangements. Furthermore, the physicians reported training needs regarding situation-independent challenges with decision-making capacity evaluation.

Conclusions

Upon further examining self-reported training needs and challenging cases, we have developed recommendations to improve decision-making capacity evaluations in clinical practice. In these recommendations, we argue that being able to evaluate decision-making capacity is an integral part of the informed consent process.

Peer Review reports

Background

Physicians have a legal and moral duty to obtain informed consent from their patients for medical treatment [1]. For a consent to be legally valid, the patient must be informed thoroughly, make a voluntary choice, and have decision-making capacity (henceforth DMC [2]). As a prerequisite to valid consent, DMC has become an indispensable pillar of modern patient-centred medicine. However, the clinical evaluation of DMC is difficult, especially in patients with dementia [3,4,5]. In dementia, cognitive impairments often limit the ability to understand, retain, and weigh different treatment options [6, 7]. For example, cognitive fluctuations are a recognised challenge to DMC evaluation [8]. Although cognitive fluctuations occur more often in cases of dementia with Lewy bodies, where it is a distinct diagnostic criterion, fluctuations in attention and memory are widely prevalent in all forms of dementia [9, 10]. Nevertheless, it has been acknowledged that being diagnosed with dementia does not render a patient incompetent per se [11,12,13].

Dementia is a common condition in the elderly population, and in light of demographic changes, it is of particular clinical importance. The World Alzheimer Report [14] estimated that the number of people affected by dementia will double every 20 years, that is, by 2040 over 80 million people will be affected by dementia [15]. As a result, DMC evaluation of patients with dementia will become an even more frequent concern for physicians. In light of this, it is important that the physicians are properly trained to evaluate DMC. However, a recent scoping review of the literature found that training of physicians on DMC and its evaluation is suboptimal [16]. In focus group interviews with physicians, the same study delved into major barriers with regard to the evaluation of DMC, including, in particular, inconsistency in approaches to DMC evaluation, and lack of knowledge about the potential ethical tension between patient autonomy and patient protection.

While theoretical aspects of DMC and instruments/tools for its evaluation have been widely researched (e.g. [17,18,19]), studies focusing on the actual DMC evaluation in clinical practice are rare [20].

Aim of the study

In the present study, we explored how physicians actually carry out DMC evaluations and what issues they perceive as challenging. In a secondary analysis of qualitative data from an interview study with physicians, we extracted difficult cases of DMC evaluations with patients with dementia from physicians’ everyday practice as well as the physicians’ self-reported training needs. This provided the basis for the discussion of challenging feature and general recommendations for physicians.

Methods

The present study is based on qualitative interviews which were part of a nationwide research project on DMC in Switzerland funded by the Swiss National Science Foundation (SNSF) (for details, see [21]). As part of this project, an evaluation instrument was developed to account not only for abilities of the patient, but to also capture physician-associated factors (e.g., intuitions, value judgements) in the decision-making process (for details, see [22,23,24]). The interviews were part of an evaluation of usability and feasibility of this instrument. As confirmed by the cantonal ethics commission of Zurich, Switzerland, in January 2015 in accordance with the Swiss Human Research Act, ethical review by the cantonal ethics commission was not required because no health-related personal data from the assessed physicians has been gathered in the present study. Written informed consent was not necessary. However, all participants consented verbally to participate.

Participants

A total of 24 healthcare professionals took part in the project of which 18 study participants were physicians. These initial participants were sampled by convenience. For the present study, we focused on the perspectives of the physicians as they are often legally responsible for the evaluation of DMC as attending physicians. We excluded the five nurses and one psychologist from the analysis. The physicians worked in internal medicine (n = 10), in psychiatry or psychiatric consultation (n = 6), or in other specialties (n = 2).

Qualitative data

All study participants received two-hour training on the concept and evaluation of DMC, for which they received six credits by the Swiss Institute for Advanced Medical Training and Education. In the subsequent four-month period, participants were asked if evaluation of DMC was an issue in their clinical practice, to use the newly developed DMC evaluation instrument to evaluate the patient’s DMC. After 4 months, face-to-face semi-structured interviews were conducted (see [21]). The main aim of the interviews was to assess qualitatively the feasibility and usability of the instrument in everyday clinical practice. Study participants were also asked about difficulties in evaluating DMC and about their perceived training needs in the evaluation of DMC. Furthermore, participants were asked to report cases from their experience during the last 4 months where the patient’s DMC was questionable. The interview language was Swiss German and interviews were conducted between April and November 2016. All interviews took place at the workplace of the study participant (e.g. hospital, general practice), during which only the interviewer and the interviewee were present. The mean length of the interviews was 45 min. Interviews were audio recorded and transcribed verbatim into written German.

Data analysis

The secondary analysis of the interview data firstly focused descriptively on the difficulties study participants reported when evaluating DMC in patients with dementia. To be within this category, it was necessary that (a) the patients who were discussed by the participants had a diagnosis of dementia, and (b) that the physician participants reported that they had significant problems in evaluating DMC in these patients. Of the 26 patient cases discussed by the 18 participants, 9 physicians discussed 11 cases fulfilling these conditions. Secondly, the answers of the same study participants with regard to their own training needs were aggregated (5 out of 9). Thirdly, the resulting data set for this paper from the above two procedures was inductively analysed with thematic analysis [25] to further understand the needs in dementia-related DMC evaluation.

One author (CP) carried out the data extractions and aggregations. All co-authors read the extracted data and discussed ethical and medical themes inherent in the physicians’ case narratives, which were grouped into three prevailing themes: (1) treatment refusals, (2) treatment unrelated circumstances, and (3) situation-independent challenges of DMC evaluation.

Findings

In this section, the clinical situations corresponding to the themes and which made DMC evaluation challenging are presented. In the next section, the ethically and medically challenging issues inherent in the aforementioned evaluation of DMC in patients with dementia are discussed. Moreover, we provide recommendations for challenging issues in the evaluation of DMC.

Clinical situations that challenge evaluation of DMC

Theme 1: when patients with dementia refuse treatment

In three of the reported challenging cases (cases 1, 6, and 8), participants described patients who refused treatment even though severe medical risk was involved in not having the treatment. In all cases, the refusal was respected by the responsible physician despite the absence of the patient’s DMC.

Case 1: An elderly patient with severe dementia refused to undergo surgery for her malignant tumour. In addition, her dementia had deteriorated before refusing to undergo surgery. The tumour was likely to grow and there was a high risk of tumour related infection. In earlier oral statements, she had also expressed her refusal of surgery. The attending physicians deemed her to lack DMC to refuse treatment. However, her daughter was present and stressed the importance to respect her wish. In the end, the physicians did not conduct the surgery.

Case 6: A patient of old age with mild dementia refused follow-up chemotherapy after tumour surgery. The physician had to inform the patient repeatedly about the risks and benefits as she had forgotten the relevant information after each appointment. The patient’s reason for deciding against the chemotherapy was that it would lead to hair loss. At each appointment, the decision not to undergo chemotherapy was consistent and she was deemed capable of decision-making.

Case 8: An elderly patient refused a surgical amputation of his gangrenous leg. As it is discussed further below, the patient underwent psychiatric consultation and was evaluated to lack DMC. In this case, there was no family member present, nor were there any advance oral statements or written directives and the refusal implied severe medical risk including death from septicaemia. Nonetheless, the physicians respected the patient’s wish which led to his death.

Theme 2: treatment-unrelated circumstances

DMC evaluations were not only found to be complicated by apparently risky treatment refusal but were reported as difficult by the study participants in several situations such as when psychiatrists had to be involved in the DMC evaluation process, DMC in the context of advance directives (AD), and DMC when patients wanted to decide further care or living arrangements.

Psychiatric consultation

In two of our cases (cases 2 and 8), the attending physician asked for psychiatric consultation to assist with DMC evaluation. In both cases the attending physician did not formally evaluate DMC and the psychiatrist declared the patient not to have DMC to make decisions. Despite this conclusion from the psychiatrist, the attending physician did not recommend the patient to undergo the indicated treatment procedure, notwithstanding apparently negative consequences for the patient if they did not have the treatment (i.e., death of the patient in case 8).

Advance directives

When writing an advance directive, DMC has to be evaluated if there is reasonable doubt that the patient might lack DMC as the advance directive is only valid if developed by a competent patient. Nevertheless, in most legal systems every adult person is presumed to have DMC (e.g., Swiss Civil Code 2018, Art. 16; UK: Mental Capacity Act 2005, section 1, 2nd principle). In Switzerland, advance directives are binding by law, but need not satisfy specific formal requirements. In advance directives, a legal guardian can be appointed. If there is no advance directive, there is cascade of guardianship among the closest family members and relatives.

In case 4, the patient was deemed unable to write an advance directive as he did not have the DMC to understand what was discussed. In this case, legal authorities became involved and a family member was appointed as his guardian. In case 10, the physician had doubts about the patient’s DMC, but the advance directive was still written due to the presence of the family who confirmed the patient’s wishes which helped the physician to conclude that the patient was competent (no further details could be extracted from the data). In case 3, a patient with moderate dementia had prepared an advance directive with a notary, in which her son was appointed as the primary guardian. She then accused her son of stealing her money. The physician could neither evaluate DMC retrospectively nor decide whether the patient had been capable of writing the advance directive. The physician could not certify the irrationality of the assertion that the patient’s son was stealing. The case was subsequently transferred to the respective legal authorities (i.e. child and adult protective services).

New living arrangements

Furthermore, DMC is often in question when new living and care arrangements for elderly patients with dementia are discussed. In case 5, an older man with dementia who had a wakened night shift wanted to leave the hospital. The physicians doubted whether he was able to care for himself at home. Two cases (cases 7 and 9) deal with patients with dementia whose circumstances were such that family members or healthcare professionals who were unable to provide the needed care at home and urged these patients to move into nursing homes. In these cases, physicians either let the patient go home under surveillance (case 5), persuaded or informed the patients repeatedly about the need to go into a nursing home (both case 7 and 9).

Theme 3: situation-independent challenges in decision-making capacity evaluation

Several of the study participants reported having had difficulties with different legal issues related to DMC evaluation. One study participant reflected:

So, I wouldn’t have known for example, or at least I wouldn’t have known it directly, that this [lack of DMC] is not required when ordering involuntary admissionFootnote 1 (mhm), hence I believe that there could be a lack of information. – Interviewee 17 (case 9).

Not knowing involuntary admission is independent of a person’s DMC is an example of lack of legal knowledge in the context of DMC evaluations, but this is not specific to dementia. For example, physicians found it difficult to evaluate DMC when the patient was subject to a guardianship order or had instated a lasting power of attorney. One participant noted that in her, falsely held, view the law might contradict itself in these cases:

I question if it is necessary for a full guardianship that the patient does not have DMC. Children and adult protection law formulate it this way.Footnote 2 This bothers me. DMC is always dependent on a certain situation and you cannot generally declare someone as not having DMC per se and put a guardianship in place. — Interviewee 2 (case 2).

Apart from uncertainty about the law with regard to DMC, the clinical evaluation of DMC was a concern for the study participants. However, a variety of instruments exist to evaluate DMC, e.g. the MacCAT-T [26]. One physician expressed the wish for accessible screening instruments in DMC evaluations:

So, I think that would be a good thing, I mean, we now work a lot with scores and such on the derma [dermatological station] to assess the severity and it is easy, and you can get training then […] sure, that training [on DMC] would be more complex and one would have to train with cases, as we did in the training session. – Interviewee 8 (case 7).

In reports about clinical evaluation of DMC, several study participants emphasised the need for economical, reliable screening instruments. Another physician stated that

it would be wonderful if there were any questionnaire with scores. I am working in assessment. I am asking 10 questions. If the patient has a score of 4, he has a depression. It would be nice if this existed [for DMC]. But I, too, don’t see how. – Interviewee 1 (case 1).

In general, the role cognitive screening instruments play in DMC evaluation is reported to be unclear, for example, whether a cut-off score can be an indicator of lack of DMC. In one case (case 4), cognitive testing alone was used to evaluate DMC.

Discussion: challenging issues raised when evaluating decision-making capacity of patients with dementia

A patient with dementia refuses treatment

In all clinical cases, treatment refusal was respected. No patient was forced into undergoing treatment. In practice, there could be a different threshold applied for refusal than for consent to treatment. Furthermore, consequences of not respecting refusal might also be graver than respecting it. This is in line with the legal “right to refuse” life-prolonging treatment [27] of competent patients. However, a prerequisite for the refusal is that the patient is able to make a considered decision. When the patient lacks DMC, physicians are morally obliged to promote the welfare of their patients. In Table 1, challenging issues of the cases are presented in which informed refusal was complicated by dementia.

Table 1 Treatment refusal in cases of dementia

A patient with dementia wants to write an advance directive

The question of DMC arises in the context of advance directives at different times. First of all, DMC is needed at the time of writing an advance directive as well as when changing it. Once a legally valid advance directive is in place, it can be open to challenge in court if there is reasonable doubt that the patient lacked DMC at the time of writing the advance directive. In Table 2, challenging issues for DMC evaluations from the cases of the present study are presented.

Table 2 Issues with advance directives

This result seems to emphasize the importance of advance care planning (ACP) in dementia, for example through general practitioners [28]. However, ACP in dementia is also challenging [29]. Indeed, the process of ACP in dementia shares the general challenges of evaluation of DMC outlined in this article, for example the involvement of family caregivers and relatives [30].

Closely related to advance directives is the question about what to do when a patient cannot be supported and cared for at home any longer. Similarly, as with advance directives, the role of the family and DMC evaluation presents a challenging issue.

A patient is unable to care for himself but wants to go home

Care decisions are treatment unrelated but nonetheless can considered as health decisions. As such, DMC is often evaluated to decide upon alternative care arrangements when the needed care cannot be provided by informal caregivers at home or outpatient nursing teams (see Table 3). These cases often need a multi-professional team effort, involving physicians and social workers alike.

Table 3 Capacity when care cannot be provided

Physicians encounter these challenging issues by finding a solution to minimise risk and maximise medical benefit. This has often little to do with a formal DMC approach. Physicians negotiate and try to get acceptance of patients for their transfer to a nursing home.

Conclusion: recommendations to address decision-making capacity evaluations of patients with dementia

Evaluation of decision-making capacity as part of the informed consent process

We recommend DMC evaluation as part of a nuanced informed consent or informed refusal process [31]. A formal DMC evaluation becomes necessary if there is reasonable doubt that the patient might lack DMC, e.g. in the case of a patient with a diagnosis of dementia. Focussing on informed consent ensures that first all reasonable steps have to be taken to provide the necessary information for the patient to decide. For example, the importance of informing the patient in a thorough and easy comprehensible manner should not be underestimated [1].

Furthermore, the physician should assess and ask the family when and where the patient is cognitively at their best, e.g. if the patient experiences confusion later in the day (‘sundowning’). If there is temporary fluctuation in attention and memory [8] the informed consent process should be repeated at least two different times before a final decision is made [32]. If sufficient information is provided and the patient still seems unable to coherently consent or refuse treatment, the physician’s clinical judgement is needed about whether or not the patient has the DMC to make decisions.

We agree that this judgement is subjective [11, 22] in the sense that the physician’s values, observations, and own experiences may influence it. It is suggested that physicians discuss these cases in case conferences and supervision sessions. This clinical judgement can also be informed by a psychiatric consultation in some cases.

Psychiatric evaluation of decision-making capacity

It has been called a myth of DMC that only a psychiatrist can evaluate DMC [33]. In cases where dementia is related to, or concomitantly present together with, severe mental disorder, psychiatric consultation is advisable. Nevertheless, DMC evaluations by psychiatric consultants are not overruling the clinical judgement of the treating physician, who retains legal responsibility for the evaluation. In addition, the attending physician (in general) is most informed of risks and benefits of the decision at hand, has known the patient the longest, and can judge best the state the patient is in. In dementia, the cognitive state of patients can also be assessed by neurologists and neuropsychologists to inform the DMC evaluation of the treating physician. If psychometric instruments such as the Mini-Mental-State-Exam (MMSE [34]) are employed, these should only be used as a decision-aid and not as stand-alone diagnostic tool for the patient’s DMC. Even the use of low cut-off scores, as is use for consent to research less than 10 of 30 in the MMSE [35], runs the risk of neglecting patients with dementia, who might have otherwise decided for themselves. Although psychometric instruments have an important place in practice, they cannot substitute clinical judgement. This clinical judgement can be supported by tools focusing on the process of DMC evaluation (e.g. from the Swiss context, the U-Doc [24]).

Solution-focused decision-making while respecting the right to autonomy

The use of solution-focused approaches if DMC is lacking is common in multifaceted medical decisions. We understand solution-focused approaches akin to a casuistic approach to decision-making based on human rights [36]. This human rights approach is different to a mental capacity/welfare-based approach because human rights such as outlined in Article 5 and 8 ECHR are independent of DMC evaluations. One example might be that “the detention of a person lacking DMC cannot be justified simply on the basis that doing so is in their best interests” [36].

Another example closer to our cases, a physician might let a patient go home even though he considers him incapable of decision-making. He might ask the patient to report back or ask family members to report about the state of the patient’s health. This way, the patient’s right of autonomy is preserved but the physician’s corresponding duty to protect the patient is served also.

Unclear at this point is what constitutes valid solution-focused approaches based on human rights without involving legal institutions. One key aspect might be good patient-physician communication, which can convince the patient of the need for further care without being paternalistic or controlling, hence infringing on the right to autonomy [37]. Furthermore, in cases where the appointment of a guardian is not possible, it might become necessary to involve social workers and the responsible legal institutions, e.g. child and adult protective services in the Swiss context. Using a right-based approach, the legal institutions, e.g., will “consider the issue from the perspective of each relevant party, explain their rights and justify, where appropriate, the interference in their rights” [36]. While solution-focused approaches do not rely solely on formal DMC evaluations, in practice this kind of decision making is of utmost importance.

Presence of relatives and the evaluation of decision-making capacity

If the physician concludes that the patient cannot consent, legal guardianship by family members or other relatives is advisable. A right-based approach has the unique advantage that it can balance conflicts between family members and, as already pointed out, does not simply overrule patient autonomy.

It is suggested that the guardianship or lasting power of attorney is appointed by, for example a court of protection. This legal recognition serves as a safeguard for family members. Furthermore, notwithstanding that the patient lacks DMC, the patient’s preferences and wishes should determine decision making as he still has a right to autonomy. In establishing patients’ preferences, family members can also serve as informants.

Conclusion

Medical and ethical aspects of right-based approaches in clinical practice are a neglected field in decision-making research. The involvement of family and relatives as guardians demand closer attention in the context of dementia. Further research should examine solution-focused decision making in a clinical context.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Notes

  1. 1.

    In Switzerland, under Art. 426 of the Civil Code, involuntary admission is possible independent of decision-making capacity. However, involuntary treatment of competent persons is not allowed.

  2. 2.

    This is actually not the case in Switzerland. Permanent absence of capacity will or could lead to full guardianship – the unofficial Swiss translation uses General Deputyship, but full guardianship does not necessarily mean permanent absence of capacity under Art. 398 of the Swiss Civil Code.

Abbreviations

AD:

Advance Directives

MacCAT-T:

MacArthur Competence Assessment Tool-Treatment

MMSE:

Mini-Mental-State-Exam

SNSF:

Swiss National Science Foundation

References

  1. 1.

    Grisso T, Appelbaum P. Assessing competence to consent to treatment. 1st ed. New York: Oxford University Press; 1998.

    Google Scholar 

  2. 2.

    Faden RR, Beauchamp TL. A history and theory of informed consent. 1st ed. New York: Oxford University Press; 1986.

    Google Scholar 

  3. 3.

    Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Diagnosis and management of Alzheimer’s disease: past, present and future ethical issues. Prog Neurobiol. 2013;110:102–13. https://doi.org/10.1016/j.pneurobio.2013.01.003.

    Article  Google Scholar 

  4. 4.

    Rodgers JJ, Kass JS. Assessment of medical decision-making capacity in patients with dementia. Continuum (Minneap Minn). 2018;24(3):920–5.

    Google Scholar 

  5. 5.

    Wendler D, Rid A. Systematic review: the effect on surrogates of making treatment decisions for others. Ann Intern Med. 2011;154(5):336–46.

    Article  Google Scholar 

  6. 6.

    Fellows LK. Competency and consent in dementia. J Am Geriatr Soc. 1998;46(7):922–6.

    Article  Google Scholar 

  7. 7.

    Moye J, Karel MJ, Azar AR, Gurrera RJ. Capacity to consent to treatment: empirical comparison of three instruments in older adults with and without dementia. Gerontologist. 2004;44(2):166–75.

    Article  Google Scholar 

  8. 8.

    Trachsel M, Hermann H, Biller-Andorno N. Cognitive fluctuations as a challenge for the assessment of decision-making capacity in patients with dementia. Am J Alzheimers Dis Other Dement. 2015;30(4):360–3.

    Article  Google Scholar 

  9. 9.

    Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease is qualitatively distinct. J Neurol Neurosurg Psychiatry. 2004;75(3):382–7.

    Article  Google Scholar 

  10. 10.

    Walker MP, Ayre GA, Cummings JL, Wesnes K, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology. 2000;54(8):1616–25.

    Article  Google Scholar 

  11. 11.

    Beattie E, O’Reilly M, Fetherstonhaugh D, McMaster M, Moyle W, Fielding E. Supporting autonomy of nursing home residents with dementia in the informed consent process. Dementia. 2018;0:1–15. https://doi.org/10.1177/1471301218761240.

    Article  Google Scholar 

  12. 12.

    Hegde S, Ellajosyula R. Capacity issues and decision-making in dementia. Ann Indian Acad Neurol. 2016;19(Suppl 1):34–9. https://doi.org/10.4103/0972-2327.192890.

    Article  Google Scholar 

  13. 13.

    Stanley B. Senile dementia and informed consent. Behav Sci Law. 1983;1(4):57–71. https://doi.org/10.1002/bsl.2370010409.

    Article  Google Scholar 

  14. 14.

    Alzheimer’s Disease International. World Alzheimer Report 2009. 2009. Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed 29 Aug 2018.

    Google Scholar 

  15. 15.

    Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7.

    Article  Google Scholar 

  16. 16.

    Charles L, Parmar J, Brémault-Phillips S, Dobbs B, Sacrey L, Sluggett B. Physician education on decision-making capacity assessment: current state and future directions. Can Fam Physician. 2017;63(1):21–30.

    Google Scholar 

  17. 17.

    Berghmans R, Dickenson D, Ter Meulen R. Mental capacity: in search of alternative perspectives. Health Care Anal. 2004;12(4):251–63.

    Article  Google Scholar 

  18. 18.

    Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER. Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry. 2006;163(8):1323–34. https://doi.org/10.1176/ajp.2006.163.8.1323.

    Article  Google Scholar 

  19. 19.

    Sessums LL, Zembrzuska H, Jackson JL. Does this patient have medical decision-making capacity? JAMA. 2011;306(4):420–7. https://doi.org/10.1001/jama.2011.1023.

    Article  Google Scholar 

  20. 20.

    Corrigan O. Empty ethics: the problem with informed consent. Soc Health Illn. 2003;25(7):768–92.

    Article  Google Scholar 

  21. 21.

    Iseli LM, Wangmo T, Hermann H, Trachsel M, Elger BS. Evaluating decision-making capacity: challenges faced by clinicians in Switzerland. GeroPsych. 2018;31(2):67–75. https://doi.org/10.1024/1662-9647/a000186.

    Article  Google Scholar 

  22. 22.

    Hermann H, Trachsel M, Biller-Andorno N. Accounting for intuition in decision-making capacity: rethinking the reasoning standard? Philos Psychiatr Psychol. 2017;24(4):313–24.

    Article  Google Scholar 

  23. 23.

    Hermann H, Trachsel M, Elger BS, Biller-Andorno N. Emotion and value in the evaluation of medical decision-making capacity: a narrative review of arguments. Front Psychol. 2016;7:765. https://doi.org/10.3389/fpsyg.2016.00765.

    Article  Google Scholar 

  24. 24.

    Hermann H, Feuz M, Trachsel M, Biller-Andorno N. Decision-making capacity: from testing to evaluation. Med Health Care Philos. 2020. https://doi.org/10.1007/s11019-019-09930-6.

  25. 25.

    Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psych. 2006;3(2):77–101.

    Article  Google Scholar 

  26. 26.

    Grisso T, Appelbaum PS. MacArthur competence assessment tool for treatment (MacCAT-T). Sarasota: Professional Resource Press/Professional Resource Exchange; 1998.

    Google Scholar 

  27. 27.

    Black I. Refusing life prolonging medical treatment and the ECHR. Oxf J Leg Stud. 2018;38(2):299–327.

    Article  Google Scholar 

  28. 28.

    Bally KW, Krones T, Jox RJ. Advance care planning for people with dementia: the role of general practitioners. Gerontology. 2020;66(1):40–6.

    Article  Google Scholar 

  29. 29.

    Bosisio F, Jox RJ, Jones L, Rubli TE. Planning ahead with dementia: what role can advance care planning play? A review on opportunities and challenges. Swiss Med Wkly. 2018;148:5152.

    Google Scholar 

  30. 30.

    Dening KH, King M, Jones L, Sampson EL. Healthcare decision-making: past present and future, in light of a diagnosis of dementia. Int J Palliat Nurs. 2017;23(1):4–11.

    Article  Google Scholar 

  31. 31.

    Spike JP. Informed consent is the essence of capacity assessment. J Law Med Ethics. 2017;45(1):95–105.

    Article  Google Scholar 

  32. 32.

    Appelbaum PS. Assessment of patients’ competence to consent to treatment. N Engl J Med. 2007;357(18):1834–40.

    Article  Google Scholar 

  33. 33.

    Ganzini L, Volicer L, Nelson WA, Fox E, Derse AR. Ten Myths about decision-making capacity. J Am Med Dir Assoc. 2005;6(Suppl 3):100–S104. https://doi.org/10.1016/j.jamda.2005.03.0212.

    Article  Google Scholar 

  34. 34.

    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

    Article  Google Scholar 

  35. 35.

    Slaughter S, Cole D, Jennings E, Reimer MA. Consent and assent to participate in research from people with dementia. Nurs Ethics. 2007;14(1):27–40.

    Article  Google Scholar 

  36. 36.

    Herring J, Wall J. Autonomy, capacity and vulnerable adults: filling the gaps in the mental capacity act. Leg Stud. 2015;35(4):698–719.

    Article  Google Scholar 

  37. 37.

    Shaw D, Elger BS. Evidence-based persuasion: an ethical imperative. JAMA. 2013;309(16):1689–90.

    Article  Google Scholar 

  38. 38.

    Federal Assembly of the Swiss Confederation. Federal Act on Research involving Human Beings (Human Research Act, HRA). 2014. https://www.admin.ch/opc/en/classified-compilation/20061313/index.html Accessed 23 May 2019.

    Google Scholar 

  39. 39.

    Swiss Federal Council. Ordinance on Human Research with the Exception of Clinical Trials (Human Research Ordinance, HRO). 2014. https://www.admin.ch/opc/en/classified-compilation/20121177/index.html. Accessed 23 May 2019.

    Google Scholar 

Download references

Acknowledgements

The authors thank Helena Hermann for conducting the interviews and Luzia Iseli for supporting data transcriptions. We are very grateful to Isra Black and Jean-François Dumoulin for providing helpful critical comments on an earlier version of this manuscript. We also thank Prof. Nikola Biller-Andorno for her support of the project.

Funding

The data presented in this paper have been gathered within the research project ‘Decision-Making Incapacity at the End of Life and its Assessment in Switzerland’ funded within the National Research Program NRP 67 ‘End of Life’ of the Swiss National Science Foundation (SNF-Grant 406740_139294). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author information

Affiliations

Authors

Contributions

All authors were involved in data analysis and discussion of ethical aspects of the cases at hand. CP drafted the manuscript. MT revised the manuscript substantially and finalised the manuscript together with CP. BE and TW substantially revised the manuscript. All authors agreed upon the manuscript.

Corresponding author

Correspondence to Manuel Trachsel.

Ethics declarations

Ethics approval and consent to participate

As confirmed by the cantonal ethics commission of Zurich, Switzerland, in January 2015 in accordance with the Swiss Human Research Act (HRA [38]), Art. 51, ethical review by the cantonal ethics commission was not required because no health-related personal data from the assessed physicians has been gathered in the present study. Thus, written informed consent was not necessary. However, all participants consented verbally to participate. If this project had been subject to the Swiss HRA, it still would have been exempt from written consent according to the Swiss Human Research Ordinance (HRO [39]), Art. 9. The patient data within this article has been completely anonymized for further use in accordance with Art. 25 of the Swiss HRO. We assume that the participants in this study had informed consent of their patients for the publication of their case narratives, but even if they did not, anonymized personal data can be used in accordance with HRO, Art. 10. The English translation of the HRO can be accessed here (https://www.admin.ch/opc/en/classified-compilation/20121177/index.html) and for the HRA here (https://www.admin.ch/opc/en/classified-compilation/20061313/index.html).

Consent for publication

All participants consented verbally to publication of the interview data. Written informed consent was not deemed necessary for this study (see above).

Competing interests

Manuel Trachsel is an Associate Editor of BMC Medical Ethics. The other authors have no conflict of interests to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Poppe, C., Elger, B.S., Wangmo, T. et al. Evaluation of decision-making capacity in patients with dementia: challenges and recommendations from a secondary analysis of qualitative interviews. BMC Med Ethics 21, 55 (2020). https://doi.org/10.1186/s12910-020-00498-y

Download citation

Keywords

  • Decision-making capacity
  • Competence
  • Dementia
  • Informed consent
  • Ethics
  • Autonomy